Aqua Pharmaceuticals has purchased the U.S. rights to skin medicine Verdeso Foam from Stiefel Laboratories Inc.
Terms of the deal were not disclosed.
Aqua Pharmaceuticals is backed by Lake Forest, Ill.-based private equity firm RoundTable Healthcare Partners. The West Chester, Penn.-based company will take over all manufacturing and distribution for Verdeso Foam and fold it into its own dermatology line, which includes other skin-care medications such as Monodox, Capsules, Xolegel Gel, Fluoroplex Topical Cream and Cordran.
The seller, Stiefel, is a subsidiary of U.K. health care company GlaxoSmithKline plc in Brentford, England. It develops products for the care and treatment of skin diseases, including atopic dermatitis, which may be treated with Verdeso Foam.
For more coverage on skincare deals in the health care sector, see “Valeant Pharmaceuticals to Stick with Skincare” as well as “The Buyside: Re-entering the Fray for Beauty Products.”